Patents by Inventor Shilan Liu
Shilan Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230405003Abstract: The present application relates to a thymidine derivative, or use of a uridine derivative in combination with a thymidine derivative in preparation of a drug for preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject. The present application further provides a method of preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject comprising administering a prophylactically or therapeutically effective amount of a thymidine derivative or uridine and thymidine derivatives to a subject in need thereof.Type: ApplicationFiled: October 29, 2021Publication date: December 21, 2023Applicant: ONQUALITY PHARMACEUTICALS CHINA LTD.Inventors: Shiyi ZHANG, Zhaoyu WU, Shilan LIU
-
Patent number: 11407717Abstract: The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 26, 2019Date of Patent: August 9, 2022Assignee: KPC PHARMACEUTICALS, INC.Inventors: Dahai Wang, Wenyuan Qian, Shilan Liu, Shuhui Chen
-
Patent number: 11236107Abstract: The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2? value, has a diffraction peak at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79°. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.Type: GrantFiled: August 17, 2018Date of Patent: February 1, 2022Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Inventors: Shilan Liu, Dahai Wang, Guibai Liang, Honglin Wang, Guoping Hu, Jian Li, Shuhui Chen
-
Patent number: 11091460Abstract: Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.Type: GrantFiled: June 14, 2018Date of Patent: August 17, 2021Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Inventors: Shilan Liu, Guibai Liang, Hongjian Wang, Ming Zhang, Shuhui Chen
-
Publication number: 20210206728Abstract: The present invention relates to benzimidazole compounds and an application thereof as IDH1 mutant inhibitors, in particular, to a compound as represented by formula (I), tautomers thereof, or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 26, 2019Publication date: July 8, 2021Applicant: KPC PHARMACEUTICALS, INC.Inventors: Dahai WANG, Wenyuan QIAN, Shilan LIU, Shuhui CHEN
-
Publication number: 20200255449Abstract: The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2? value, has a diffraction peak at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79°. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.Type: ApplicationFiled: August 17, 2018Publication date: August 13, 2020Inventors: Shilan LIU, Dahai WANG, Guibai LIANG, Honglin WANG, Guoping HU, Jian LI, Shuhui CHEN
-
Publication number: 20200199101Abstract: Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.Type: ApplicationFiled: June 14, 2018Publication date: June 25, 2020Applicant: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Inventors: Shilan LIU, Guibai LIANG, Hongjian WANG, Ming ZHANG, Shuhui CHEN
-
Patent number: 10487088Abstract: Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.Type: GrantFiled: February 20, 2017Date of Patent: November 26, 2019Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Medshine Discovery Inc.Inventors: Shilan Liu, Dahai Wang, Guibai Liang, Guoping Hu, Jian Li, Shuhui Chen
-
Patent number: 10246457Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: GrantFiled: April 4, 2016Date of Patent: April 2, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Tony Siu, Michael D. Altman, Brian M. Andresen, Jian Liu, Joseph Kozlowski, Sobhana Babu Boga, Younong Yu, Rajan Anand, Jiaqiang Cai, Dahai Wang, Shilan Liu
-
Publication number: 20190062338Abstract: Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.Type: ApplicationFiled: February 20, 2017Publication date: February 28, 2019Inventors: Shilan Liu, Dahai Wang, Guibai Liang, Guoping Hu, Jian Li, Shuhui Chen
-
Patent number: 10214546Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: GrantFiled: December 17, 2015Date of Patent: February 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Jian Liu, Joseph A. Kozlowski, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
-
Patent number: 10208047Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.Type: GrantFiled: December 17, 2015Date of Patent: February 19, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Jian Liu, Joseph A. Kozlowski, Brian M. Andresen, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
-
Patent number: 10130630Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: GrantFiled: December 17, 2015Date of Patent: November 20, 2018Assignee: MERCK SHARP & DOHME CORP.Inventors: Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Rajan Anand, Sobhana Babu Boga, Deodial Guy Guiadeen, Wensheng Yu, Younong Yu, Shilan Liu, Hao Wu, Chundao Yang
-
Patent number: 10087188Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: GrantFiled: December 17, 2015Date of Patent: October 2, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jyhshing Wang, Wensheng Yu, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
-
Patent number: 10040805Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.Type: GrantFiled: December 17, 2015Date of Patent: August 7, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Jian Liu, Joseph A. Kozlowski, Xiaolei Gao, Deodial Guy Guiadeen, Shilan Liu, Dahai Wang
-
Publication number: 20180141962Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set forth herein. The present invention also provides pharmaceutical compositions comprising these compounds and their use in therapy. In Cparticular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated dis orders.Type: ApplicationFiled: April 4, 2016Publication date: May 24, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: JIAN LIU, JOSEPH KOZLOWSKI, RONALD KIM, XIAOLEI GAO, SOBHANA BABU BOGA, YOUNONG YU, HAO WU, SHILAN LIU, CHUNDAO YANG
-
Publication number: 20180127411Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: ApplicationFiled: April 4, 2016Publication date: May 10, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Tony SIU, Michael D. ALTMAN, Brian M. ANDRESEN, Jian LIU, Joseph KOZLOWSKI, Sobhana Babu BOGA, Younong YU, Rajan ANAND, Jiaqiang CAI, Dahai WANG, Shilan LIU
-
Publication number: 20180118766Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.Type: ApplicationFiled: December 17, 2015Publication date: May 3, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, XIAOLEI GAO, DEODIAL GUY GUIADEEN, JIAQIANG CAI, SHILAN LIU, DAHAI WANG, HAO WU, CHUNDAO YANG
-
Publication number: 20180079752Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.Type: ApplicationFiled: May 31, 2016Publication date: March 22, 2018Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.Inventors: ADRIANUS PETRUS ANTONIUS DE MAN, RONALD KIM, JIAN LIU, JOSEPH A. KOZLOWSKI, SOBHANA BABU BOGA, THIERRY FISCHMANN, DEODIAL Guy GUIADEEN, ILSE HENDRICA MARIA POLS-DE ROOIJ, SHILAN LIU, HAO WU
-
Publication number: 20180009828Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.Type: ApplicationFiled: December 17, 2015Publication date: January 11, 2018Applicant: MERCK SHARP & DOHME CORP.Inventors: JIAN LIU, JOSEPH A. KOZLOWSKI, XIAOLEI GAO, DEODIAL GUY GUIADEEN, SHILAN LIU, DAHAI WANG